The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.